Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.